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Usher syndrome type I is characterized by congenital hearing loss, retinitis pigmentosa (RP), and variable vestibular
areflexia. Usher syndrome type ID, one of seven Usher syndrome type I genetic localizations, have been mapped
to a chromosomal interval that overlaps with a nonsyndromic-deafness localization,DFNB12.Mutations inCDH23,
a gene that encodes a putative cell-adhesion protein with multiple cadherin-like domains, are responsible for both
Usher syndrome and DFNB12 nonsyndromic deafness. Specific CDH23 mutational defects have been identified
that differentiate these two phenotypes. Only missense mutations of CDH23 have been observed in families with
nonsyndromic deafness, whereas nonsense, frameshift, splice-site, and missense mutations have been identified in
families with Usher syndrome. In the present study, a panel of 69 probands with Usher syndrome and 38 probands
with recessive nonsyndromic deafness were screened for the presence of mutations in the entire coding region of
CDH23, by heteroduplex, single-strand conformation polymorphism, and direct sequence analyses. A total of 36
different CDH23 mutations were detected in 45 families; 33 of these mutations were novel, including 18 missense,
3 nonsense, 5 splicing defects, 5 microdeletions, and 2 insertions. A total of seven mutations were common to more
than one family. Numerous exonic and intronic polymorphisms also were detected. Results of ophthalmologic
examinations of the patients with nonsyndromic deafness have found asymptomatic RP–like manifestations, in-
dicating that missense mutations may have a subtle effect in the retina. Furthermore, patients with mutations in
CDH23 display a wide range of hearing loss and RP phenotypes, differing in severity, age at onset, type, and the
presence or absence of vestibular areflexia.
Introduction
Usher syndrome is a frequent cause of recessive syndromic
deafness and is estimated to account for (a) 3%–6% of
the congenitally deaf population (Vernon 1969), (b)
∼18% of those with retinitis pigmentosa (RP), and (c)
150% of the deaf-blind population (Boughman et al.
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1983). The frequency of Usher syndrome has been esti-
mated to be 3.5/100,000 in Sweden and Finland (Nuutila
1970; Grondahl 1987), 3.2/100,000 in Colombia (Ta-
mayo et al. 1991), and 4.4/100,000 in the United States
(Boughman et al. 1983).
The standard classification of Usher syndrome rec-
ognizes three distinct clinical categories (Kimberling and
Moller 1995). Type I is manifested by severe to pro-
found congenital hearing impairment, vestibular dys-
function, and retinal degeneration beginning in child-
hood, whereas type II is manifested by moderate to
severe hearing impairment, normal vestibular function,
and later onset of retinal degeneration; type III, the least
common form of Usher syndrome, presents with pro-
gressive hearing loss and a variable retinal and vestib-
ular phenotype.
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Table 1
Twelve Novel Mutations in the CDH23 Gene Observed in 9 of 38
Probands with RNSD
Nucleotide
(Codon) Change Exon Domain
Proportion of
Chromosomes Family
371ArG (D124G) 5 EC1 1/214 1846
1355ArG (N452S) 13 EC4 1/214 3055
1439TrA (L480Q) 13 EC5 1/214 2640
1745GrA (R582Q) 15 EC6 1/214 1194
3178CrT (R1060W) 26 EC10 1/214 3063
3557GrA (G1186D) 29 EC11 1/214 2640
4756GrC (A1586P) 37 EC15 2/214 PKDF030
4783GrA (E1595K) 37 EC15 1/214 1566
5536GrA (D1846N) 42 EC17 1/214 3055
6442GrA (D2148N) 47 EC20 3/214 3409, 1668
7393CrT (R2465W) 52 EC23 1/214 1846
7823GrA (R2608H) 54 EC24 1/214 1668
At least seven different USH1 genes are responsible for
the more severe, type I syndrome. These genes have been
mapped to chromosomes 10q21.1, 10q22.1, 11q13.5,
11p15.1, 14q32, 17q24-25, and 21q21 (see the Hered-
itary Hearing Loss Homepage). There are no studies re-
porting clinical differences between these seven forms,
but they are differentiated on the basis of either linkage
analysis in informative families or mutational analyses
of the genes involved. Currently, four USH1 genes have
been identified. Defects in myosin VIIa, harmonin, cad-
herin 23, and protocadherin 15 are responsible for caus-
ing Usher syndrome type I subtypes B, C, D, and F, re-
spectively (Weil et al. 1995; Bitner-Glindzicz et al. 2000;
Verpy et al. 2000; Ahmed et al. 2001; Alagramam et al.
2001; Bolz et al. 2001; Bork et al. 2001).
In 1996, by homozygosity mapping of an inbred
Pakistani family, Wayne et al. localized USH1D (MIM
601067) to the long arm of chromosome 10 (Wayne et
al. 1996), a chromosomal region that also contained
DFNB12 (MIM 601386), a nonsyndromic-deafness lo-
calization (Chaib et al. 1996). Mutations in CDH23
(MIM 605516) cause both Usher syndrome type ID and
DFNB12. Missense mutations were found exclusively
in five consanguineous families with nonsyndromic
deafness (Bork et al. 2001) and in a sixth, large con-
sanguineous family with nonsyndromic deafness (A. P.
M. Brouwer, R. J. E. Pennings, M. Roeters, P. Van
Hauwe, L. M. Astuto, L. H. Hoefsloot, P. L. M. Huygen,
B. van den Helm, A. F. Deutman, J. M. Bork, W. J.
Kimberling, F. P. M. Cremers, C. W. R. J. Cremers, and
H. Kremer, unpublished data [hereafter referred to as
“Brouwer et al., unpublished data”]). Splicing variants,
deletions, nonsense mutations, and missense mutations
of CDH23 have been identified in patients with Usher
syndrome type I (Bolz et al. 2001; Bork et al. 2001; von
Brederlow et al. 2002).
CDH23 has 69 exons and encodes a predicted 3,354-
amino-acid protein with 27 cadherin extracellular (EC)
repeats, a transmembrane domain, and a unique cyto-
plasmic domain. The product of CDH23 has similarity
to the well-characterized protein E-cadherin; the EC re-
peats of E-cadherin are responsible for homophilic cell-
cell adhesion, which is established by the formation of
parallel stable EC-domain dimers at the same cell sur-
face and at two opposing cell surfaces. This stability is
due to interdomain rigidification of the EC domains,
achieved by the binding of three calcium ions to highly
conserved peptide sequences (LDRE, DXNDN, and
DXD) (Nollet et al. 2000). The functions of cadherin
23 have not been defined, but it is hypothesized to be
involved in the establishment of cell-cell contacts and
in the organization of the EC matrix.
In the present study, we sought to further investigate
the genotype/phenotype relationship, proposed by Bork
et al. (2001), between CDH23 mutations and the con-
sequent hearing, visual, and vestibular phenotype. Using
a comprehensive mutation-detection strategy via het-
eroduplex, SSCP, and direct sequence analyses of all 69
exons from 107 probands, we were able to gain insight
into the distribution and nature of diverse CDH23 mu-
tations and their resulting phenotypes.
Subjects, Material, and Methods
Subjects and Clinical Studies
A total of 107 families with Usher syndrome and re-
cessive nonsyndromic deafness (RNSD), comprising 281
unaffected and 173 affected members, were sampled and
studied; 12 families were consanguineous. A total of 68
families (48 with Usher syndrome type ID and 20 with
DFNB12) were multiplex and compatible with linkage
to the USH1D region; and the remaining 39 families
were characterized by sporadic cases (21 with Usher syn-
drome type I and 18 with RNSD). The 38 families with
RNSD were drawn from an original population of 157
families referred with nonsyndromic hearing loss to Boys
Town National Research Hospital. In all families, mu-
tations in MYO7A and GJB2 were excluded by linkage
and/or mutational analysis. Families were collected in
the United States (57 families), Sweden (17 families), The
Netherlands (10 families), Germany (10 families), Spain
(3 families), Pakistan (3 families), South Africa (2 fam-
ilies), France (2 families), Italy (2 families), and Ireland
(1 family). Several of these families were part of three
previous studies (Kelley et al. 1998; Astuto et al. 2000;
Bork et al. 2001). Not all individuals in the present study
were sequenced for all 69 CDH23 exons.
Cases were included on the basis of the following cri-
teria: (1) both parents had normal hearing, and (2) the
proband’s hearing loss was moderate to profound. Pa-
tients with Usher syndrome meet the further criteria of
presenting with evidence of RP, including extinguished or
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Table 2
Mutations in the CDH23 Gene Observed in 35 of 69 Probands with Usher Syndrome
Nucleotide
(Codon) Change Exon Domain
Proportion of
Chromosomes Family
Missense mutations:
3617CrG (P1206R) 30 EC11 1/214 1078
3625ArG (T1209A) 30 EC11/EC12a 2/214 220
5237GrA (R1746Q)b 40 EC16/EC17a 6/214 792, 809, 2790, 3308
7549ArG (S2517G) 53 EC23/EC24a 1/214 1056
8230GrA (G2744S) 57 EC26 1/214 1054
8497CrG (R2833G) 58 EC26 1/214 980
9524GrA (R3175H) 67 CYTO 1/214 3051
Splicing variants:
IVS41GrA 4 EC1 13/214 1185, 1197, 1285, 1288, 1289, 1291, 1321, 1324
1450GrCc (A484P) 14 EC5 2/214 1517
IVS201GrA 20 EC7 3/214 1066, 2059, 3036
3105ArCc (T1035T) 25 EC10 1/214 2059
4488GrCc (Q1496H)b 35 EC14 1/214 1444
IVS459GrAb 46 EC19 7/214 1071, 3036, 3150, PKSRB, PKSR13a
7872GrAc (E2624E) 54 EC25 1/214 2797
Nonsense:
172CrT (Q58X) 3 EC1 1/214 1291
4504CrT (R1502X) 36 EC14 5/214 1184, 1197, 1198, 1288
6307GrT (E2103X) 47 EC20 1/214 3150
Deletions:
193delC 3 EC1 1/214 216
1087delG 10 EC4 2/214 2738
1112delT 10 EC4 2/214 359, 792
6155delC 46 EC19 1/214 1130
6968delC 49 EC22 1/214 51
Insertions:
3840insATGA 31 EC12 1/214 216
9626insC 68 CYTO 1/214 897
a Mutation lies within linker region between these two EC-repeat domains.
b Mutations reported by either Bolz et al. (2001) or von Brederlow (2002).
c Detected at either beginning or end of the exon, predicted to decrease splicing efficiency.
subnormal electroretinography (ERG) recordings. We re-
fer to typical families with Usher syndrome type I as those
presenting with profound deafness, RP, and absent ves-
tibular function; atypical families are categorized as hav-
ing a milder affliction in one or more of the three sensory
systems (hearing, balance, and vision) involved. Two fam-
ilies with Usher syndrome type II were also included.
Computed-tomography scans of the inner ear were also
obtained for several families, and the results were normal
in all cases. For each family, a pedigree was drawn. Clin-
ical data were collected from medical histories and/or ex-
aminations, either at Boys Town National Research Hos-
pital in Omaha or by various collaborators at their local
clinical facilities. The local human-subjects committees
approved the present study, and informed consent was
obtained from all participants.
Blood Collection and DNA Extraction
Blood samples were collected, and genomic DNA was
extracted by a Puregene kit (Gentra Systems).
PCR Conditions
Oligonucleotide primers designed by Bolz et al. (2001)
and Bork et al. (2001) were used for PCR and for cycle-
sequencing reactions. PCR elements were as follows: 1
# reaction buffer, 200 mM each dNTP, 2.5 mM MgCl2,
5 pmol of each forward and reverse primer, and 0.5 U
of Taq DNA polymerase. PCR conditions were as fol-
lows: 95C for 10 min, followed by 35–40 cycles of 95C
for 30 s, 55–65C for 30 s, and 72C for 60 s, followed
by a final extension at 72C for 10 min.
Heteroduplex Analysis (HA)
PCR products amplified from syndromic and nonsyn-
dromic probands and cloned control DNA were mixed,
heated at 95C for 3 min, and cooled to 25C during a
45-min period. The reannealed reaction products were
then electrophoresed through a 35-cm# 43-cm# 1-mm
volume of MDE (FMC) gel, at an average of 900 V for
18–24 h, were stained with 1 mg of ethidium bromide/
ml, and were visualized under UV light. RP11-472K8
BAC DNA (AC016823) was amplified for each CDH23
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Table 3
Presumed Nonpathogenic Variants in CDH23
INTRONIC VARIANTS EXONIC VARIANTS
Nucleotide Change
Exon-Specific
PCR Product
Nucleotide
(Codon) Change Exon
IVS-121CrT 1 7CrT (R3C) 1
IVS-88ArC 1 198GrA (V66V) 3
c.-1CrT 1 366TrC (V122V) 5
IVS112CrT 1 1038GrA (P346P) 10
IVS513GrA 5 1053CrT (S351S) 10
IVS526ArG 5 1469GrC (G490A) 14
IVS641CrA 6 1487GrA (S496N) 14
IVS664CrT 6 2316TrC (N772N) 21
IVS8101GrA 8 2388TrC (D796D) 21
IVS924GrA 10 3009TrC (S1003S) 25
IVS1013ArG 10 3231TrG (P1077P) 27
IVS11107ArT 12 3664GrA (A1222T) 30
IVS1189CrT 12 4051GrA (D1351N) 31
IVS1412GrA 15 4299TrA (P1433P) 34
IVS1547TrC 16 4310GrA (R1437Q) 34
IVS1679ArG 16 4341TrC (D1447D) 34
IVS16220CrT 17 4723GrA (A1575T) 37
IVS1646TrC 17 4858GrA (V1620M) 38
IVS1840GrT 19 5023GrA (V1675I) 38
IVS1821CrG 19 5100CrT (Y1700Y) 39
IVS1919GrA 20 5411GrA (R18804Q) 41
IVS20135CrT 20 5541CrT (N1847N) 42
IVS2126TrC 21 5660CrT (T1887I) 42
IVS2317CrT 24 5996CrG (T1999S) 45
IVS2560CrT 26 6130GrA (E2044K) 46
IVS2912CrT 30 6197GrA (R2066Q) 46
IVS31183GrC 32 6315CrT (V2105V) 47
IVS31160CrT 32 6847GrA (V2283I) 49
IVS3183ArG 32 6918GrA (L2306L) 49
IVS3353TrC 34 7073GrA (R2358Q) 50
IVS3371CrT 34 7139CrT (P2380L) 50
IVS3532CrG 35 7467CrT (R2489R) 52
IVS37135CrT 38 7572GrA (A2524A) 53
IVS3779GrA 38 7762GrC (E2588Q) 54
IVS3749TrC 38 8798TrA (V2933E) 60
IVS3848GrC 39 8860GrA (D2954N) 60
IVS3944CrG 39 8885ArG (N2962S) 60
IVS3973CrT 39 8895CrT (P2965P) 60
IVS4144TrC 42 8907CrT (R2969R) 60
IVS4110ArG 42 9015GrA (A3005A) 61
IVS4881GrA 49 9873GrA (T3291T) 69
IVS526GrA 52
IVS5825GrA 58
IVS6014CrA 61
IVS618GrA 61
exon and was used as a control. Mixing with BAC control
DNA prior to heteroduplex formation allows the detec-
tion of both homozygous and heterozygous mutations. A
set of 96 genetically independent control samples of mixed
European ancestry also was studied, to aid in differenti-
ation between probable pathologic mutations and poly-
morphisms. The controls were obtained through a read-
ing-disability research project in which no history of
hearing or visual loss had been identified. If the mutation
was found in one or more of the 96 control samples, it
was considered to be nonpathologic.
SSCP Analysis
SSCP analysis was performed on several CDH23
exons. The amplified DNA was run on 5% polyac-
rylamide gels, with 10% glycerol, in 1 # Tris-borate
EDTA. Samples were electrophoresed either at 45 W, in
a cold room, or at 40 W, with cooling electrophoresis
equipment (Gibco-BRL). A set of 96 normal independent
genomic control samples was also studied, to aid in the
identification of probable pathologic mutations and in
the differentiation between them and polymorphisms.
DNA Sequencing
PCR products showing band shifts in SSCP and/or HA
were purified and concentrated by Microcon 100 filters
(Millipore) and Millipore 96-well filter plates, prior to
sequencing. ABI Prism BigDye Terminator Cycle Sequenc-
ing Ready Reaction kits (Perkin Elmer) were used to gen-
erate sequence from both purified PCR products and BAC
DNA templates. Five microliters of PCR products were
sequenced with 4 pmol of CDH23 primers, 3 ml of ABI
Ready Reaction mix, and 5 # buffer, in a total volume
of 10 ml, for 35 cycles of 95C for 10 s, 50C for 5 s, and
60C for 4 min. Products of the sequencing reactions were
precipitated and resuspended in a 5:1 ratio of formamide/
dye loading buffer. Two microliters were loaded onto
4.8% PAGE-PLUS (Amresco) sequencing gels and were
run on the ABI Prism model 377 DNA sequencer, ac-
cording to ABI protocols. Sample files were generated by
ABI Sequencing Analysis 3.0. Fractura 2.0 (ABI) was used
to remove ambiguous sequences. Contig assembly was
performed by the DNASTAR SeqMan 5.03 program. In
some cases, direct sequencing could not unequivocally
identify the DNA sequence change; for those cases, PCR
products were cloned into a plasmid vector (TOPO TA
Cloning Kit; Invitrogen), to separate individual alleles
prior to sequencing.
Splicing Program
All IVS changes were analyzed by the BDGP splice-
site–prediction program (available at the Berkeley Dro-
sophila Genome Project Splice Site Prediction by Neu-
ral Network Web site). IVS sequence changes that
predict a loss of splicing-acceptor or -donor activity
and that are not present in control samples are con-
sidered pathologic.
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Figure 1 Alignment of cadherin 23 EC domains with missense mutations causing Usher syndrome type ID and recessive DFNB12.
DNASTAR Lasergene and the program of The Sequence Manipulation Suite were used to align 14 EC domains. Corresponding EC domains
are indicated to the left of the lineup. Dark-gray–shaded residues are 190% identical in all sequences; light-gray–shaded residues are 70%
conserved in all aligned sequences. The LDRE, DXNDN, and DXD calcium-binding motifs are boxed. The sites of missense mutations identified
in the present study (tables 1 and 2) are highlighted in yellow (in the case of DFNB12) and red (in the case of USHID).
Results
Mutational Analyses
Two hundred fourteen chromosomes were screened
for mutations in CDH23, by a combination of hetero-
duplex, SSCP, and/or sequencing analyses. A total of 36
different CDH23 mutations were identified in 45 fam-
ilies. Tables 1 and 2 list the mutations observed in, re-
spectively, the families with DFNB12 and the families
with Usher syndrome type ID. Table 3 lists the presumed
nonpathogenic variants in CDH23. Codon numbering
starts with the first in-frame methionine of the human
CDH23 (GenBank accession number AF312024; Bolz
et al. 2001).
Nonsense mutations.—Three mutations causing pre-
mature stop codons were identified in six probands with
Usher syndrome type ID. Heterozygous nucleotide sub-
stitutions resulted in two premature stop codons—Q58X
and E2103X, in exons 3 and 47, respectively. A 4504CrT
transition, producing R1502X in exon 36, was identi-
fied exclusively in four Swedish families. Genealogical re-
search revealed that all four families originated from or
near the Va¨sterbotten region in northern Sweden, sug-
gesting a founder effect for R1502X.
Deletions/insertions.—Seven mutations that created a
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Table 6
Summary of CDH23 Mutations Identified in Present Study and in Patients Who Elsewhere Have Been Reported as Being Affected with
Either RNSD or Usher Type I
Mutation Domain Phenotypea Reference
Q58X EC1 Usher syndrome type I Present study
193delC EC1 Atypical Usher syndrome Present study
IVS41GrA EC1 Usher syndrome type I, atypical Usher syndrome Present study
D124G EC1 RNSD Present study
1087delG EC4 Usher syndrome type I Present study
1112delT EC4 Atypical Usher syndrome Present study
N452S EC4 RNSD Present study
L480Q EC5 RNSD Present study
A484P EC5 Usher syndrome type Ib Present study
R582Q EC6 RNSD Present study
IVS201GrA EC7 Atypical Usher syndrome Present study
D990N EC9 RNSD Bork et al. (2001)
T1035T EC10 Atypical Usher syndrome Present study
R1060W EC10 RNSD Present study
G1186D EC11 RNSD Present study
P1206R EC11 Usher syndrome type I Present study
T1209A EC11/EC12c Usher syndrome type Ib Present study
3840insATGA EC12 Atypical Usher syndrome Present study
A¨M1281 EC12 Usher syndrome type I Bolz et al. (2001)
Q1294X EC12 Usher syndrome type I Bork et al. (2001)
D1341N EC13 RNSD Brouwer et al. (unpublished data)
Q1496H EC14 Usher syndrome type I Bolz et al. (2001)
R1502X EC14 Usher syndrome type I, atypical Usher syndrome Present study
A1586P EC15 RNSD Present study
E1595K EC15 RNSD Present study
R1746Q EC16/EC17c Atypical Usher syndrome Bolz et al. (2001); present study
D1846N EC17 RNSD Present study
T1904T EC18 Usher syndrome type I von Brederlow et al. (2002)
IVS451GrA EC19 Usher syndrome type I Bork et al. (2001)
IVS459GrA EC19 Usher syndrome type I, atypical Usher syndrome von Brederlow et al. (2002); present study
D2045N EC19 RNSD Bork et al. (2001)
6155delC EC19 Atypical Usher syndrome Present study
E2103X EC20 Usher syndrome type Ib Present study
R2107X EC20 Usher syndrome type I Bork et al. (2001)
D2148N EC20 RNSD Brouwer et al. (unpublished data)
D2202N EC21 RNSD Bork et al. (2001)
6933delT EC21 Usher syndrome type I von Brederlow et al. (2002)
6968delC EC22 Atypical Usher syndrome Present study
IVS515GrA EC23 Usher syndrome type I Bolz et al. (2001); von Brederlow et al. (2002)
R2465W EC23 RNSD Present study
S2517G EC23/EC24c Usher syndrome type Ib Present study
R2608H EC24 RNSD Present study
E2624E EC25 Usher syndrome type Ib Present study
G2744S EC26 Atypical Usher Present study
R2833G EC26 Atypical Usher syndrome Present study
I2950N EC27 RNSD Bork et al. (2001)
R2956C EC27 RNSD Bork et al. (2001)
P3059T EC27-TMd RNSD Bork et al. (2001)
IVS661GrA CYTO Atypical Usher syndrome Bork et al. (2001)
R3175H CYTO Usher syndrome type Ib Present study
9626insC CYTO Usher syndrome type I Present study
a Further described in tables 4 and 5.
b Family was referred with a diagnosis of Usher syndrome type I, but no specific clinical data were available.
c Mutation lies within linker region between these two EC-repeat domains.
d Mutation lies between EC27 and transmembrane domain.
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frameshift leading to a subsequent premature stop codon
were identified in seven probands with Usher syndrome.
One mutation, 9626insC, is located in the cytoplasmic
domain. Sequence analysis of family 216 identified a
maternally inherited 4-base insertion of an ATGA be-
tween nucleotide position 3840 and nucleotide position
3841 in exon 31, resulting in a deduced TGA stop codon
eight amino acids downstream. The insertion of these
nucleotides also alters codon 1281, the same methionine
codon that Bolz et al. (2001) previously had reported to
be deleted in a patient who was compound heterozygous
for Usher syndrome.
Splice-site mutations.—Seven splice-site defects were
detected, two of which accounted for the most frequent
mutations in CDH23. An IVS41GrA mutation of the
splice-donor site of exon 4 was detected in eight Swedish
families. The frequency of IVS41GrA in the Swedish
probands suggests that it may also be a Swedish founder
CDH23 mutation. Haplotype conservation of the two
Swedish mutations is currently under study.
The second most frequentCDH23mutation identified
in the present study is an IVS459GrA mutation of the
splice-acceptor region preceding exon 46. Exon-trapping
experiments done by von Brederlow et al. (2002) have
revealed aberrant splicing creating a novel acceptor
splice site 9 bp upstream of the 5′ end of the exon, con-
sequently resulting in the insertion of 7 bp from the 3′
end of intron 45. Another mutation disrupting the con-
served donor splicing sequence is an IVS201GrA tran-
sition found in one allele of three independent families.
The four remaining predicted splicing defects are nu-
cleotide substitutions occurring at the first or last nu-
cleotide of an exon. One of these mutations, Q1496H,
a mutation that has been reported elsewhere, is hetero-
zygous in one of the Spanish probands. Published exon-
trapping experiments have shown that this mutation
causes the use of a cryptic intronic splice site used down-
stream of the GrC nucleotide substitution (Bolz et al.
2001).
Missense mutations.—A total of 19 different missense
mutations were detected in our study; 12 were identified
in families with RNSD, and the remaining 7 were iden-
tified in families with Usher syndrome type I. Each mis-
sense mutation identified in the probands with Usher
syndrome was compound heterozygous with a presumed
null allele, except for two cases: one family was ho-
mozygous for T1209A, and two families were homo-
zygous for R1746Q; each presents an atypical Usher
syndrome phenotype (Bolz et al. 2001; present study).
An American family with RNSD was compound het-
erozygous for two missense mutations inCDH23:D124G
in exon 5 and R2465W in exon 52. Amino acid alignment
of several cadherin 23 domains reveals that the D124G
mutation disrupts a conserved DXNDN calcium-binding
motif in the first EC domain. Likewise, the R2465W mu-
tation disrupts the LDRE calcium-binding motif in the
23rd EC domain (fig. 1). Molecular modeling (Brouwer
et al., unpublished data) of the R2465W mutation shows,
furthermore, an interrupted intra- and interdomain salt
bridge, which should strongly reduce the interaction be-
tween EC23 and EC24 and which therefore may change
the tertiary structure required for proper cadherin 23
function.
A homozygous D2148N was identified in one Dutch
family with RNSD; an American family was heterozy-
gous for the mutation. Restriction digestion with BsiEI
confirmed segregation of this DFNB12 variant in both
families with RNSD (data not shown). Additional EC
alignments of these mutations revealed the amino acids
to be conserved (fig. 1), and molecular modeling also
indicates impairment in calcium binding (Brouwer et al.,
unpublished data). The remaining eight DFNB12 mu-
tations are listed in table 1.
Seven different missense mutations were identified
among 11 typical and atypical families with Usher syn-
drome type I. Eight of these families were found to have
missense mutations that were compound heterozygous
with a null allele. Six of the seven missense mutations
in probands with Usher syndrome type ID were iden-
tified in the EC domains; the seventh missense mutation
was found in the cytoplasmic domain. All Usher syn-
drome missense mutations are listed in table 2. None of
the CDH23 missense mutations found in patients with
Usher syndrome interfered with calcium-binding sites,
in contrast to what was seen for the missense mutations
found in patients with DFNB12; however, two of the
substitutions did disrupt conserved amino acids (fig. 1).
Clinical Analyses
RNSD is defined as hearing impairment with no
other identified organ-system involvement. Typical
Usher syndrome type I is profound deafness, RP verified
by an extinguished ERG, and absent bilateral vestibular
function that first manifests as delayed (i.e., at age 118
mo) age at ambulation. Clinical investigations of both
of our sample groups demonstrate a remarkable range
of phenotypic variation. Clinical summaries presented
in tables 4 and 5 contain only those families for which
relevant audiologic, vestibular, and ophthalmologic ex-
aminations and documentation could be obtained; no
anamnestic information is included, with the exception
of the developmental reports of ages at independent
ambulation.
DFNB12 phenotype.—Probands with DFNB12 and
their affected siblings show a less severe phenotype, com-
pared with the probands with Usher syndrome. During
their later years, they present a hearing loss ranging from
moderate (40–60 dB) to profound (190 dB) deafness. In
two families, hearing loss had progressed from a mild
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(!40 dB) loss during childhood. In table 4, six individuals
with DFNB12 present with moderate to severe hearing
loss, five individuals show severe to profound hearing loss,
and one consanguineous family has profound hearing
loss. The age at diagnosis of sensorineural hearing loss in
affected members has been documented as being 3 mo–6
years, suggesting an onset that is not congenital in all
cases. Intrafamilial variation in hearing is also evident, as
demonstrated in family 1668, in which serial audiograms
of two affected brothers show a progressive hearing loss,
with onset at age 4 years in one and at age 6 years in the
other; the hearing loss progressed from moderate to se-
vere, bilaterally, in the older brother but progressed asym-
metrically, from severe to profound, just in the left ear of
the younger brother. All patients with DFNB12 had been
able to walk at age12 mo, and subsequent examinations
have shown normal vestibular function. However, ERG,
visual-field analysis, and/or fundus examination results
demonstrated a subjectively mild retinal attenuation and/
or slightly subnormal, or low-amplitude, ERG response;
however, there is no visual-field deficit, and only one of
five families tested has night blindness. The retinal pa-
thology can be subtle, as is the case in family 1194 (ta-
ble 4): although ERG results for affected members were
normal, one of two pediatric ophthalmologists noticed
slightly narrowed retinal arterioles with underlying gran-
ular pigment epithelium; despite the fact that vision scores
in dim light were below normal and that each individual
complained of night-blindness difficulties, the subnormal,
albeit mild, fundus-examination results were reported as
falling within normal limits. Consequently, this family had
been referred to the Boys Town National Research Hos-
pital laboratory, with a diagnosis of RNSD.
Usher syndrome type I phenotype.—A remarkably di-
verse phenotype was observed in the patients with Usher
syndrome type I. Although the mildest phenotype was
consistently seen in families with DFNB12, families with
Usher syndrome that carry an array of mutations dem-
onstrated considerable variation in hearing, vision, and
balance (table 5).
The majority of patients with Usher syndrome who
were tested had congenital profound deafness. Six indi-
viduals with Usher syndrome type I deviated from this
phenotype. Two families with Usher syndrome had severe
hearing loss, two families had severe to profound hearing
loss, one family had one affected individual with moderate
to severe hearing loss and had a second affected individual
with moderate to profound hearing loss. In these six in-
dividuals, serial audiologic data showed progression and
asymmetry in two cases.
Age at ambulation was 10–36 mo in patients with
Usher syndrome. Balance ability of 19 individuals with
Usher syndrome type I was determined by ENG, calorics
and/or examination in a rotary chair. All patients with
typical Usher syndrome type I show a late age at am-
bulation, 18–36 mo, and no vestibular reflexes. One atyp-
ical patient, who had been able to walk at age 19 mo,
presented with mild vestibular dysfunction. Balance-abil-
ity testing of five atypical cases, who had been able to
walk at age 10–15 mo, demonstrated normal vestibular
function.
Of 37 patients with Usher syndrome type I on whom
ERG tests and/or fundus examinations were performed,
26 showed extinguished, or flat, ERG amplitudes, 19
had typical RP manifestations in the fundus, and 8 had
subnormal ERG responses. Subnormal RP-like findings
in the retina were found in four patients. One proband
had a normal ERG response; the fundus examination of
another proband with subnormal ERG amplitudes in-
dicated a normal retina.
A collection of visual-field tests were examined, and
rates of progression were quantified and categorized ac-
cording to a classification system described by Grover
et al. (1997). For those cases in which visual fields could
not be determined, verbal descriptions of the testing re-
sults are given in table 5. Of the 34 individuals for whom
visual-field data were available, 20 show a marked con-
centric loss of 10 in both eyes, or oculi unitas (OU)
(type 4). Eight patients presented a concentric central-
field loss with a temporal island, or scotoma OU (type
3). Partial peripheral restrictions OU (type 5) were iden-
tified in two Swedish individuals with Usher syndrome
type I, at ages 75 and 80 years. Another Swedish pro-
band, at age 47 years, had a midperipheral complete-
ring scotoma OU (type 2) that had not progressed since
age 19 years.
Clinical analyses of cases with the R1746Q missense
mutation show a variable retinal phenotype similar to that
described by Bolz et al. (2001). An American family, 3308,
homozygous for the R1746Q mutation originally was re-
ferred to our laboratory through the RNSD research pro-
ject. This 5-year-old boy presented with congenital pro-
found deafness but had been able to walk at age 19 mo.
Clinical investigation and examination in a rotary chair
revealed a mildly hypoactive vestibular response. Al-
though the results of an ERG at age 3.5 years were nor-
mal, follow-up examinations are being recommended, to
determine whether a diagnosis of Usher syndrome type I
is valid. An Irish family, 809, also homozygous for
R1746Q, presented with mild late-onset RP. Ophthal-
mologic examinations of members of family 792, who
were compound heterozygous for R1746Q and 1112delT,
revealed a severe course of RP. Interestingly, late-onset RP
was seen in the 73-year-old father, who was heterozygous
for the R1746Q allele. Ophthalmologic examinations of
the father revealed a flat ERG, a nonpigmentary and dif-
fuse atrophy of the fundus, and visual fields of !5. The
father did not present with hearing loss. No other indi-
viduals in this family who were heterozygous forCDH23
reported visual problems or any other carrier effect; how-
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ever, the father has been tested only for mutations in exon
40 of CDH23, and the possibility exists that (a) another
CDH23 mutation exists or (b) mutations in another RP
gene are responsible for his condition. Family 2790, het-
erozygous for R1746Q, presented atypical Usher features:
the hearing loss is asymmetric and severe to profound,
and results of ERG tests were subnormal at age 29 years,
despite a documented 10 visual-field result. Fundus ex-
amination revealed typical RP, and, although vestibular
testing was not completed, the affected individual in this
family reportedly had been able to walk at age 13 mo.
The following clinical findings for families 980 and
2059 underscore the fact that the severity of the phe-
notypes can be highly variable and may overlap with
Usher syndrome types II and III. Swedish family 980 was
referred to our molecular-testing lab as having Usher syn-
drome type II. The 49-year-old singleton proband present-
ed with a sloping moderate to profound hearing loss and
normal developmental milestones and vestibular function.
The serial visual data for this individual show a late onset
and slow progression of RP. On the basis of the variable
retinal phenotype associated with mutations of CDH23,
these retinal findings prompted us to include this proband
in our analysis, and, indeed, a heterozygous R2833G mis-
sense mutation was identified; however, the second mu-
tation has not yet been identified. Family 2059 was orig-
inally referred to our laboratory as having RNSD. One
of the two affected siblings had a severe asymmetrical
hearing loss at age 14 years, and the other had a moderate
to severe hearing loss at age 8 years; both showed pro-
gressive hearing loss. Subsequent testing for mutations in
GJB2 was negative. Genotyping analysis was consistent
with linkage to the 10q region, and therefore our test-
ing included this family, as putatively having DFNB12.
While the mutation screening was in progress, visual
exams revealed extinguished and subnormal ERG re-
sponses, as well as abnormal fundus-examination find-
ings, in each affected individual. Because of reported nor-
mal developmental milestones and normal vestibular
function, the diagnosis was changed to Usher syndrome
type II, but testing for mutations in CDH23 continued.
Family 2059 simultaneously underwent preliminary anal-
ysis for mutations in USH2A, until two splice-site mu-
tations, IVS201GrA and 3105ArC (T1035T), were
identified in CDH23.
The remarkable phenotype of family 1054 has been
reported elsewhere (Bitoun et al. 1991). Two affected
children born of Sephardic Jewish first cousins have a
heterozygous G2744S mutation and presented with ret-
inal degeneration. A severe hearing loss and an extin-
guished ERG, typical of RP, were identified in the older
proband; the younger brother has a subnormal ERG
response, with normal fundus-examination findings and
normal hearing. The lack of a homozygous CDH23 mu-
tation in this consanguineous family, the identification
of only one missense mutation, G2744S, and the ad-
ditional clinical findings of developmental delay, dys-
morphism, and severe ataxia suggest either a non–Usher
syndrome diagnosis or the existence of another syn-
drome; therefore, until a second mutation is been iden-
tified, we are hesitant to claim that this family has Usher
syndrome type ID.
Discussion
In 27 (56.3%) of 48 multiplex families with Usher syn-
drome and in 6 (30%) of 20 multiplex families with
RNSD, we have identified CDH23 mutations that link
to chromosome 10q21.1-q22.1, which includes the
USH1D, DFNB12, USH1F, and DFNB23 loci (Chaib
et al. 1996; Wayne et al. 1996, 1997; Hereditary Hearing
Loss Homepage). Mutations were seen in six sporadic
cases of Usher syndrome type I and in five sporadic cases
of RNSD. Forty-one families with Usher syndrome type
I were part of a previous study (Astuto et al. 2000) in
which results of linkage and heterogeneity analyses sug-
gested that the chromosome 10q–associated Usher syn-
drome type I subtype was the second most common
Usher syndrome type I subtype. Our CDH23 mutation
analysis has corroborated those findings. On the basis
of the proportion of CDH23 mutations among fami-
lies with RNSD, it should be noted that the sample is
refined, since cases with mutations of GJB2, SLC26A4,
or OTOF have been excluded. Extrapolating from an
original population of 157 families with RNSD, we es-
timate that 5% of RNSD is caused by mutations in
CDH23. Technical error or hidden mutations in gene
regions that we did not explore—regions such as introns
and regulatory regions—may account for the individuals
who carry single CDH23 heterozygous mutations. The
possibility also exists that these individuals are CDH23
carriers and that the causative mutation is at a different
locus, such as USH1F.
The majority of CDH23 mutations occur within the
CDH23-gene region encoding the EC domain. Muta-
tions were identified in all domains except the signal
sequence. Only one mutation in the cytoplasmic domain
had been previously identified (Bork et al. 2001); the
remainder of the mutations occur in the EC repeats. We
have identified two additional mutations in the cyto-
plasmic domain—R3175H and 9626insC—both asso-
ciated with an Usher syndrome type I phenotype.
The distribution and location of the missense mu-
tations identified in the present study illustrate that the
mutations do not cluster within one domain. Howev-
er, comparison of the locations between phenotypic
groups show that 6 of 12 DFNB12 missense muta-
tions change the highly conserved peptide sequences
LDRE, DXNDN, and DXD, which are responsible for
calcium-binding and rigidification (fig. 1). Molecular
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modeling of five of these amino acid substitutions
strongly suggests that there is a defect in Ca2 ion
binding (Brouwer et al., unpublished data). No Usher
syndrome type ID missense mutations change the con-
served calcium-binding sequences, and only two of six
EC-domain mutations substitute a conserved amino
acid (fig. 1).
Conclusions drawn from the present study and from
other groups (Bolz et al. 2001; Bork et al. 2001; Brou-
wer et al., unpublished data) show that missense mu-
tations produce a less severe phenotype, both in families
with Usher syndrome type I and in families with RNSD,
whereas nonsense, splice-site, and frameshift mutations
produce a more severe Usher syndrome type I phenotype
(table 6). In our mutation data, a reduced frequency of
null mutations of CDH23 is seen as the phenotype be-
comes milder. Approximately 88%, 67%, and 0% of
null mutations of CDH23 are found in typical Usher
syndrome type I, in atypical Usher syndrome type I, and
in probands with RNSD, respectively. However, the ge-
notype does not always predict the clinical phenotype,
which varies both within and between families carrying
the same CDH23 mutations, implying the existence of
other genetic and/or environmental factors that influ-
ence phenotype.
The lack of a distinct Usher syndrome type ID phe-
notype may complicate mutation analysis of all patients
diagnosed with Usher syndrome types I–III. In the pres-
ent study, we have identified a CDH23 mutation in an
individual diagnosed with Usher syndrome type II. We
therefore plan to test a series of cases with an Usher
syndrome type II phenotype, to determine the frequency
of CDH23 mutations within this diagnostic category.
Identification of progressive hearing loss and variable
balance dysfunction in patients excluded from harbor-
ing identified Usher syndrome type III mutations are
also candidates for CDH23 mutation screening. Effi-
cient mutation testing will be difficult because of the
complexity of the CDH23-gene structure. However,
some mutations of CDH23 occur with high frequency
in certain populations. For example, R1502X and the
IVS41GrA should be the first two CDH23 mutations
screened in patients with Usher syndrome who have a
Swedish background.
The syndromic and nonsyndromic association found
inCDH23 alleles is not exclusive to this gene. Two other
Usher syndrome type I subtypes are allelic with DFNB
loci: DFNB2 is associated with USH1B (Liu et al. 1997;
Weil et al. 1997), and DFNB18 is associated with
USH1C (Ahmed et al., in press). Understanding the var-
iations of pathophysiology underlying mutations of
CDH23, as well as the other Usher syndrome genes, is
paramount if effective treatments are to be developed.
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